Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 4 Interventional

Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network

NCT00930150
View directory record Official record
Conditions
Schizophrenia
Interventions
Targeted cognitive training, Computer control, Bridging groups, Health and wellness groups
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
New Haven, Connecticut • Atlanta, Georgia • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 4 Interventional Results available

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

NCT01929889
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 25, 2026, 10:41 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

ERG Components in Schizophrenia and Bipolar Disorder Type I

NCT03788811
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
ERG assessment (RSPA)
Device
Lead sponsor
diaMentis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
11
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

NCT05389787
View directory record Official record
Conditions
Schizophrenia, Cerebellar Function, Condition
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis

NCT03975400
View directory record Official record
Conditions
Schizophrenia, First Episode Psychosis
Interventions
search engine advertisement campaign
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Glen Oaks, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder
Interventions
Probiotic Supplement, Inert Compound
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

NCT02331433
View directory record Official record
Conditions
Schizophrenia
Interventions
APN1125, Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Motivational Interviewing for Loved Ones

NCT04010747
View directory record Official record
Conditions
Psychotic Disorders, Psychosis, Psychotic Episode
Interventions
Motivational Interviewing for Loved Ones (MILO), Mental Health Services Consultation and Waitlist
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 4 Interventional

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

NCT00177008
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2007 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional

The Police-Mental Health Linkage System

NCT03740139
View directory record Official record
Conditions
Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
Interventions
The Police-Mental Health Linkage System
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 25, 2026, 10:41 AM EDT
Terminated Not applicable Interventional

Deep Brain Stimulation in Treatment Resistant Schizophrenia

NCT02361554
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Medtronic Percept with SensSight Deep Brain Stimulation System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Schizophrenia

NCT01810783
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342
View directory record Official record
Conditions
Schizophrenia
Interventions
PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Rogers, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 10:41 AM EDT
Withdrawn Phase 2 Interventional

L-arginine Study for Persistent Symptoms of Schizophrenia

NCT04054973
View directory record Official record
Conditions
Schizo Affective Disorder, Schizophrenia
Interventions
L-arginine, Sapropterin Dihydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Effects In Schizophrenic Smokers

NCT00548470
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder, Nicotine Dependance
Interventions
Varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

NCT01646827
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 2 Interventional

Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia

NCT00404573
View directory record Official record
Conditions
Schizophrenia
Interventions
RGH-188
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis

NCT01981356
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Acceptance and Commitment Therapy, Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 25, 2026, 10:41 AM EDT
Not yet recruiting Not applicable Interventional

Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder

NCT07488156
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffective Disorder, Psychosis
Interventions
Educational sessions
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

NCT01530529
View directory record Official record
Conditions
Healthy
Interventions
PF-05180999
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 25, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional

Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy

NCT06835556
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Cognitive Behavioral Therapy, TAU
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

Targeting Auditory Hallucinations With Alternating Current Stimulation

NCT03221270
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
tACS treatment week, tACS sham week, Maintenance tACS, Maintenance Sham tACS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 25, 2026, 10:41 AM EDT